WAM
ACOR

Wolverine Asset Management’s Acorda Therapeutics ACOR Stock Holding History

Wolverine Asset Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-186
Closed -$16K – 1840
2020
Q2 		$16K Hold
186
– – ﹤0.01% 1385
2020
Q1 		$20K Buy
+186
New +$36.6K ﹤0.01% 1287
2019
Q2 		– Sell
-201
Closed -$320K – 1639
2019
Q1 		$320K Sell
201
-256
-56% -$461K ﹤0.01% 964
2018
Q4 		$853K Buy
+457
New +$994K 0.01% 872

Other funds holding ACOR

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Wolverine Asset Management's ACOR Position: Q3 2020 in Review

Wolverine Asset Management sold out of Acorda Therapeutics (ACOR) in Q3 2020, closing a stake of 186 shares — an estimated $16K sold.

Wolverine Asset Management first reported a position in ACOR in Q4 2018 and held it in 4 quarters. The position peaked at $853K in Q4 2018. 60 funds tracked by Wall St. Rank hold ACOR as of Q3 2020.

  • Wolverine Asset Management reported no remaining Acorda Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Wolverine Asset Management sold 186 Acorda Therapeutics shares in Q3 2020, an estimated $16K.
  • Wolverine Asset Management first reported a position in Acorda Therapeutics in Q4 2018 and held it in 4 quarters.
  • Wolverine Asset Management's Acorda Therapeutics position peaked at $853K in Q4 2018.
  • 60 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2020.

Based on Wolverine Asset Management's 13F filing for Q3 2020, filed 13 Nov 2020.